Sigyn Therapeutics, Inc. announced the completion of an invitro blood purification study that validated the ability of Sigyn Therapy to eliminate bloodstream toxins associated with Hepatic Encephalopathy, a neurological disorder that occurs in individuals suffering from chronic forms of liver (hepatic) disease and acute liver failure. Sigyn Therapy is a proprietary blood purification technology designed to deplete a broad-spectrum of pathogens, toxins and inflammatory targets from the bloodstream of treated patients. Hepatic Encephalopathy (HE) is induced when toxins (normally removed by a healthy liver) accumulate in the bloodstream and then cross through the blood brain barrier. Severe cases of HE (grade 3 and 4) can cause serious, life-threatening complications that range from decreased consciousness to coma. 30-day mortality rates of 38% have been reported in cirrhotic patients suffering from grade 3 and 4 Hepatic Encephalopathy. The goal of the hepatic toxin study was to collect supporting data that would expand the potential use of Sigyn Therapy to include chronic liver disease and acute liver failure indications, including HE.